Company intelligence / Profile preview

Marathon Asset Management

New York, NY, USA

Ownership: Private
Employees: ~190
Development stage: Other

Overview

Marathon Asset Management is a leading global asset manager with $23B AUM, primarily investing in credit and fixed income. It is not a product/platform company and does not have a clinical-stage pipeline. It invests in, finances, or acquires stakes in life science companies and pharmaceutical royalty streams (e.g. Kaléo, Endo Inc, deals with Aquestive Therapeutics).

Industry: Investors

Partnerships

Institutional investorsUS Treasury (PPIP Fund)KaléoAquestive TherapeuticsEndo Inc

Beyond the preview

Go deeper on Marathon Asset Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Marathon Asset Management.

Explore the full profile